Johnson & Johnson (JNJ) Cash from Investing Activities Growth (1y) (2010 - 2026)
Johnson & Johnson (JNJ) Cash from Investing Activities Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Investing Growth (1y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
-16.79% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-250.17% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
21.90% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
-43.02% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-586.62% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
-60.18% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
526.51% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
-76.02% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Biogen |
30.87 Bn |
26.59 Bn |
1.82 Bn |
-342.92% |
| Date | Value |
|---|
| Mar 29, 2026 |
-250.17% |
| Dec 28, 2025 |
-239.77% |
| Sep 28, 2025 |
82.67% |
| Jun 29, 2025 |
-33.44% |
| Mar 30, 2025 |
35.99% |
| Dec 29, 2024 |
-9.82% |
| Sep 29, 2024 |
-223.10% |
| Jun 30, 2024 |
-262.47% |
| Mar 31, 2024 |
-114.00% |
| Dec 31, 2023 |
86.72% |
| Apr 2, 2023 |
191.22% |
| Apr 3, 2022 |
-1,864.32% |
| Oct 3, 2021 |
43.58% |
| Jul 4, 2021 |
94.43% |
| Apr 4, 2021 |
68.16% |
| Jan 3, 2021 |
-488.02% |
| Sep 27, 2020 |
-192.95% |
| Jun 28, 2020 |
-320.69% |
| Mar 29, 2020 |
59.00% |
| Dec 29, 2019 |
-160.32% |
